NYU Langone Health Study Begins on Cryotherapy Device for Adenomyosis
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Channel Medsystems, Inc. announced grant support for an investigator-sponsored study at NYU Langone Health’s Center for Fibroid Care. The study is evaluating the Cerene® Cryotherapy Device in women with MRI-confirmed adenomyosis. Taraneh Shirazian, who serves as Director of the Center for Fibroid Care, is the Principal Investigator for the study.
From manilatimes.net
Why it matters
The investment supports the company’s clinical strategy and is backed by its recent $30 million Series C financing. The study is a prospective, single-arm observational evaluation of the device’s effectiveness for treating bleeding and pelvic pain associated with adenomyosis.
From manilatimes.net
Who's involved
- Taraneh ShirazianPrincipal Investigator and Director of Center for Fibroid Care at NYU Langone Health
- NYU Langone HealthHospital hosting the investigator-sponsored study
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- New cryotherapy study may challenge UPMC's adenomyosis treatment protocolsThe University of Pittsburgh Medical Center may need to adjust protocols if the Cerene cryotherapy study succeedsPossible
- New adenomyosis study may provide clinical evidence for BMJThe study's findings could provide new clinical evidence for BMJ readers.Possible
Keep exploring
The entities involved
-
NYU Langone Health
hospital in New York, United States
Nothing else this week.